PMV Pharmaceuticals, Inc. (PMVP) Prices 11.765M Share IPO at $18/Sh

PMV Pharmaceuticals, Inc. (NASDAQ: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the pricing of its initial public offering of 11,765,000 shares of common stock at a public offering price of $18.00 per share. PMV Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on September 25, 2020 under the ticker symbol “PMVP.”

The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by PMV Pharma, are expected to be approximately $211.8 million. The offering is expected to close on September 29, 2020, subject to the satisfaction of customary closing conditions. In addition, PMV Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,764,750 shares of common stock at the initial public offering price less the underwriting discounts and commissions.

Goldman Sachs & Co. LLC, BofA Securities, Cowen and Evercore ISI are acting as joint book-running managers for the offering.

A registration statement relating to the shares being sold in the offering was filed with the United States Securities and Exchange Commission and became effective on September 24, 2020.

You May Also Be Interested In

• Goldman, BofA vie to manage Anthropic employee wealth post-IPO - report
• Thomson Reuters prices $1.3B U.S. notes and C$1B Canadian notes
• Redwood Trust prices $185M convertible notes due 2030